| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Methyl 1H-pyrrole-2-carboxylate does not have a defined pharmacological target as it is a synthetic intermediate and fragment molecule. The compound is used as a building block for synthesizing HIV-1 active pyrrolyl aryl sulfones and anti-mitotic combretastatin A-4/lamellarin T hybrids. As a pyrrole derivative, it serves as a scaffold for designing novel drug candidates targeting various biological targets including HIV protease and microtubules.
|
|---|---|
| ln Vitro |
No direct in vitro pharmacological activity data are available for methyl 1H-pyrrole-2-carboxylate as it is a synthetic intermediate. In research settings, the compound is used as a building block for synthesizing libraries of pyrrole-based compounds that are subsequently screened for biological activity. Its activity is assessed in terms of synthetic utility and reactivity rather than direct biological activity.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for methyl 1H-pyrrole-2-carboxylate as it is not a therapeutic agent. The compound is used in chemical synthesis and is not administered directly to animals. Its derivatives, including HIV-1 active compounds and anti-mitotic agents, may be evaluated in animal models.
|
| Enzyme Assay |
For non-cellular assays, methyl 1H-pyrrole-2-carboxylate is characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry to confirm identity and purity. The compound can be evaluated as a substrate in various organic reactions including esterification, amidation, and coupling reactions. Typical protocols involve dissolving the compound in appropriate solvents and analyzing reaction products by chromatographic methods. Purity is typically >95%. The compound has a molecular weight of 125.13 and molecular formula C6H7NO2.
|
| Cell Assay |
For in vitro cell-based studies, methyl 1H-pyrrole-2-carboxylate is not typically used as a direct test compound. The compound is used as a building block for synthesizing biologically active molecules such as HIV-1 inhibitors and anti-mitotic agents that are subsequently tested in cell-based assays. If handled in a biological laboratory context, standard safety precautions should be taken.
|
| Animal Protocol |
For in vivo animal studies, methyl 1H-pyrrole-2-carboxylate is not administered directly as a test compound. The compound is used in chemical synthesis to produce pharmaceutical candidates that are subsequently evaluated in animal models. Storage: keep in a cool, dry place protected from light and moisture. Standard handling procedures for pyrrole derivatives should be followed.
|
| ADME/Pharmacokinetics |
Methyl 1H-pyrrole-2-carboxylate has a molecular weight of 125.13 and molecular formula C6H7NO2. It has an MDL number of MFCD00817048 and PubChem CID of 2735089. Purity: typically >95%. Storage: keep in a cool, dry place protected from light and moisture. The compound is a solid at room temperature.
|
| Toxicity/Toxicokinetics |
Methyl 1H-pyrrole-2-carboxylate is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
1H-pyrrole-2-carboxylic acid methyl ester is a member of the pyrrole class of compounds.
Methyl 1H-pyrrole-2-carboxylate (CAS 1193-62-0) is also known as 1H-pyrrole-2-carboxylic acid methyl ester and methyl pyrrole-2-carboxylate. It has an MDL number of MFCD00817048. The compound is used as an intermediate for HIV-1 active pyrrolyl aryl sulfones and anti-mitotic combretastatin A-4/lamellarin T hybrids. No clinical trials or therapeutic approvals exist for the parent compound. |
| Molecular Formula |
C6H7NO2
|
|---|---|
| Molecular Weight |
125.13
|
| Exact Mass |
125.047
|
| CAS # |
1193-62-0
|
| PubChem CID |
136930
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
230.3±13.0 °C at 760 mmHg
|
| Melting Point |
74-78ºC
|
| Flash Point |
93.1±19.8 °C
|
| Vapour Pressure |
0.1±0.5 mmHg at 25°C
|
| Index of Refraction |
1.527
|
| LogP |
1.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
9
|
| Complexity |
114
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=CN1)OC
|
| InChi Key |
VONGYFFEWFJHNP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7NO2/c1-9-6(8)5-3-2-4-7-5/h2-4,7H,1H3
|
| Chemical Name |
methyl 1H-pyrrole-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.9917 mL | 39.9584 mL | 79.9169 mL | |
| 5 mM | 1.5983 mL | 7.9917 mL | 15.9834 mL | |
| 10 mM | 0.7992 mL | 3.9958 mL | 7.9917 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
